Latest news with #Cepheid
Malaysian Reserve
18 hours ago
- Health
- Malaysian Reserve
Molecular Point-of-Care (mPOC) Market Reaches $1.8 Billion: Kalorama Report Spotlights Rapid PCR Innovation and Expanding Frontiers in STI and HAI Testing
ARLINGTON, Va., June 20, 2025 /PRNewswire/ — Kalorama Information, a leading authority in in vitro diagnostics (IVD) market research, has released Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029, estimating the global mPOC market at $1.8 billion in 2024. The report offers a comprehensive forecast through 2029, highlighting transformative opportunities in respiratory, sexually transmitted, and hospital-acquired infection diagnostics at or near the point of care. 'While the molecular point-of-care market saw unprecedented acceleration during the COVID-19 pandemic, Kalorama's latest analysis reveals it now stands on a firmer foundation with renewed growth expected,' said Justin Saeks, senior market analyst and report author. 'We anticipate an almost double-digit compound annual growth rate for the 'true' mPOC segment as demand spreads beyond COVID to broader respiratory panels, STIs, HAIs, and tropical diseases.' Key Findings from the Report: Respiratory testing dominates the market, with COVID-19, flu, strep, and RSV continuing to drive system adoption, particularly for combination tests. Growth expected in HAIs and STIs, although these will evolve more slowly due to testing infrastructure and workflow differences across care settings. 'True' mPOC segment revenues, which had recently declined, are projected to achieve a substantial CAGR from 2024 to 2029. Kalorama differentiates between 'true' mPOC platforms and near-patient systems, offering detailed segmentation by company, region, and disease target. Abbott and Cepheid lead their respective segments. True mPOC Systems: Compact, fast, CLIA-waived (or with waiver potential), and operable by non-lab personnel. Key players include Abbott (market leader), Roche, Cepheid, QuidelOrtho, BioFire, and Sekisui. Near-Patient Molecular Systems: Encompasses larger non-POC systems and smaller platforms with POC or near-POC potential. BioFire and Cepheid are major competitors, with Cepheid leading this segment. Why It Matters Now The report's release is timely as healthcare providers seek diagnostic solutions that balance speed, accuracy, and accessibility across both developed and resource-limited settings. mPOC systems bring the power of molecular testing to emergency departments, outpatient clinics, nursing homes, mobile labs, and even homes—enabling timely treatment decisions and improving care outcomes. 'POC molecular diagnostics represent one of the most important intersections between innovation and access in global health,' said Alisa Alvich, Marketing Director at Science and Medicine Group, Kalorama Information's parent company. 'Kalorama's analysis shows where this market is headed and what players must consider to stay competitive.' Audience Impact This research is essential for: Product Managers and R&D leaders developing decentralized molecular platforms. Corporate strategy teams evaluating new market opportunities or CLIA-waived innovations. Investors and M&A professionals scouting high-growth segments or acquisition targets. Clinical lab and procurement teams optimizing test menus for decentralized care delivery. With deep dives into market sizing, disease applications, regional dynamics, and competitive intelligence, Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 equips life sciences professionals with the insights needed to navigate a rapidly evolving diagnostics frontier. Get the Report Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024–2029 is now available for purchase at: For purchasing inquiries or to schedule a custom consultation, contact:Sheri Davie – Sales Director, Kalorama About Kalorama Information Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website.
Yahoo
04-06-2025
- Business
- Yahoo
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1 "Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https:// About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries:Darwa SOURCE Cepheid View original content to download multimedia: Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Cision Canada
04-06-2025
- Business
- Cision Canada
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert ® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert ® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030. 1 "Xpert ® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert ® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert ® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578 About Cepheid Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit
Yahoo
04-06-2025
- Business
- Yahoo
Cepheid Receives Health Canada Licence for Xpert® HIV-1 Viral Load XC
Next-Generation Molecular Test for Monitoring Viral Load and HIV-1 Infection SUNNYVALE, Calif., June 4, 2025 /CNW/ -- Cepheid today announced that Health Canada has issued Cepheid a medical device licence for Xpert® HIV-1 Viral Load XC, a next-generation extended-coverage (XC) test intended to aid in assessing HIV viral load levels, which are used to monitor effectiveness of antiretroviral treatment. Xpert® HIV-1 Viral Load XC dual target test provides extended strain coverage ensuring a high level of performance with a simple workflow to improve patient access to the standard of care and help achieve UNAIDS HIV targets by 2030.1 "Xpert® HIV-1 Viral Load XC leverages dual target technology to improve detection while maintaining the flexibility to be performed on-demand in as little as 90 minutes." said Vitor Rocha, President of Cepheid. "Access to the test can enhance patient care, as measurement of HIV viral load informs treatment plans while fast results enable earlier interventions with counseling and therapy." The test is designed for use on any of Cepheid's GeneXpert® Systems which provide simple, reference lab quality PCR testing on location in laboratory environments at medical centers and hospitals or in community health clinics and physician offices. Xpert® HIV-1 Viral Load XC will begin shipping to customers in Canada in June 2025. Visit for more information. Malisa et al 2023 Nature Scientifc Reports | (2023) 13:4578https:// About CepheidBased in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is an operating company within Danaher Corporation's Diagnostics platform. Cepheid is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit IVD. In Vitro Diagnostic Medical Device. May not be available in all countries For Cepheid Media Inquiries:Darwa SOURCE Cepheid View original content to download multimedia:
Yahoo
23-04-2025
- Business
- Yahoo
DHR Q1 Earnings: Bioprocessing Momentum and Tariff Strategy Drive Guidance Above Expectations
Diversified science and technology company Danaher (NYSE:DHR) announced better-than-expected revenue in Q1 CY2025, but sales were flat year on year at $5.74 billion. Guidance for next quarter's revenue was better than expected at $5.92 billion at the midpoint, 1.4% above analysts' estimates. Its non-GAAP profit of $1.88 per share was 14.4% above analysts' consensus estimates. Is now the time to buy DHR? Revenue: $5.74 billion vs analyst estimates of $5.59 billion (flat year on year, 2.7% beat) Adjusted EPS: $1.88 vs analyst estimates of $1.64 (14.4% beat) Adjusted EBITDA: $1.88 billion vs analyst estimates of $1.66 billion (32.7% margin, 13.3% beat) Revenue Guidance for Q2 CY2025 is $5.92 billion at the midpoint, above analyst estimates of $5.83 billion Adjusted EPS guidance for the full year is $7.68 at the midpoint, roughly in line with what analysts were expecting Operating Margin: 22.2%, in line with the same quarter last year Free Cash Flow Margin: 18.4%, down from 25% in the same quarter last year Organic Revenue fell 4% year on year, in line with the same quarter last year Market Capitalization: $137.5 billion Danaher's first quarter results were shaped by resilient bioprocessing demand and stronger-than-expected respiratory testing volumes at Cepheid. Management credited the company's recurring revenue streams and diversified end markets for stabilizing performance despite flat overall sales. CEO Rainer Blair highlighted ongoing investments in innovation and capacity, noting, 'The Danaher Business System continues to help us deliver productivity and share gains even as global markets remain dynamic.' Looking ahead, Danaher's guidance for the next quarter is supported by anticipated stability in end markets and continued operational discipline. The company expects to offset current tariff impacts by adjusting supply chains, implementing surcharges, and optimizing manufacturing locations. Blair emphasized that, 'We believe providing adjusted EPS guidance offers the best anchor point for assessing business performance,' reflecting a preference for cautious optimism given the uncertain macroeconomic environment. Danaher's leadership focused on the durability of its business model and execution of its long-term strategy, particularly as macroeconomic and geopolitical conditions remain fluid. The flat revenue trend was offset by notable outperformance in bioprocessing and higher-than-anticipated demand in diagnostics, while ongoing cost discipline and new product launches also shaped results. Bioprocessing Segment Momentum: The bioprocessing division delivered high-single digit growth, driven by strong commercial demand for consumables, particularly from large pharmaceutical and contract manufacturing customers. Order momentum remained positive for the seventh consecutive quarter, reinforcing management's confidence in the business's ability to deliver high-single digit growth in 2025 and beyond. Diagnostics Resilience and Product Launches: Cepheid's respiratory testing business exceeded expectations due to elevated illness levels, while new diagnostic products targeting cancer research (PD-L1, HER2 antibodies) and point-of-care molecular tests supported growth. Beckman Coulter's FDA clearance for a new chemistry analyzer expanded offerings for lower-volume laboratories. Life Sciences Mixed Performance: Life Sciences instruments saw stable demand in pharma, clinical, and applied markets, but softness in academic and government spending, especially in the United States, weighed on results. Management noted that government and academic revenue comprises a small portion of total sales, limiting overall impact. Tariff and Supply Chain Strategy: Danaher is proactively addressing tariff headwinds—estimated in the hundreds of millions of dollars—by regionalizing manufacturing, adjusting trade flows, and deploying surcharges. CFO Matt McGrew highlighted that these actions are designed to largely offset current tariff impacts. Disciplined Capital Allocation and M&A: The company maintains a preference for mergers and acquisitions as its primary use of capital but remains cautious given valuation uncertainty in the current environment. Management emphasized that a strong balance sheet positions Danaher to act when attractive opportunities arise. Danaher's outlook for the next quarter and full year centers on stable end market demand, with low-single digit revenue growth expected in Q2 and full-year adjusted EPS guidance set at $7.60 to $7.75. Bioprocessing and Consumables Growth: Management expects continued high-single digit growth in bioprocessing, underpinned by robust demand for consumables and a steady order pipeline. New capacity expansions are set to support both current and future customer needs. Tariff Mitigation Measures: The company's ability to offset tariff impacts through supply chain shifts, surcharges, and manufacturing changes is expected to help protect margins, though management cautioned that further escalation could require more aggressive actions. Life Sciences and Diagnostics Trends: While academic and government demand may remain soft, management anticipates stability in pharma and clinical segments, with new product launches and commercial execution in diagnostics providing incremental growth drivers. Michael Ryskin (Bank of America): Asked whether bioprocessing growth was more consumables or equipment-driven; management replied that consumables led growth, while equipment orders and funnels are improving but remain below historical levels. Tycho Peterson (Jefferies): Inquired about Danaher's ability to pass on price increases in the context of tariffs; CFO Matt McGrew explained that pricing is expected to be flat due to volume-based procurement in diagnostics, and surcharges for tariffs are not included in base pricing assumptions. Scott Davis (Melius Research): Sought color on China's long-term margin structure after procurement changes; CEO Rainer Blair said China remains an attractive diagnostics market, with pricing now in line with global averages. Doug Schenkel (Wolfe Research): Questioned the sustainability of margin guidance and sources of cushion; management confirmed some conservatism in guidance, with cost savings and FX tailwinds providing flexibility if macro conditions remain stable. Rachel Vatnsdal (J.P. Morgan): Asked about weakness in U.S. academic and government demand in Life Sciences; management noted this segment is a small revenue contributor and further softness is already factored into guidance. In the coming quarters, the StockStory team will be monitoring (1) sequential bioprocessing order growth and capacity utilization as indicators of continued demand, (2) the company's effectiveness in mitigating tariff-related cost pressures through operational actions, and (3) the trajectory of academic and government spending within Life Sciences. Progress on new product rollouts and any M&A activity will also serve as important signals for Danaher's execution against its strategic plans. Could DHR exceed our expectations? The answer lies in our free research report. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Comfort Systems (+751% five-year return). Find your next big winner with StockStory today. Sign in to access your portfolio
